Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Natàlia Vilor‐Tejedor, Alyssa Stevensson et al.|JAMA Neurology|2021Cited by 627
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detectedMarc Suárez‐Calvet, Natàlia Vilor‐Tejedor, Carolina Minguillón et al.|EMBO Molecular Medicine|2020Cited by 411
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid testsNicolas R Barthélemy, Oskar Hansson, Gemma Salvadó et al.|Nature Medicine|2024Cited by 401
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s diseaseMarta Milà‐Alomà, Kaj Blennow, Nicholas J. Ashton et al.|Nature Medicine|2022Cited by 349
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareSebastian Palmqvist, Oskar Hansson, Pontus Tideman et al.|JAMA|2024Cited by 317